Monitoring for Lack of Benefit: A Critical Component of a Randomized Clinical Trial
- 1 February 2009
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 27 (4), 629-633
- https://doi.org/10.1200/jco.2008.17.8905
Abstract
To balance patient interests against the need for acquiring evidence, ongoing randomized clinical trials are formally monitored for early convincing indication of benefit or lack of benefit. In lethal diseases like cancer, where new therapies are often toxic and may have limited preliminary efficacy data, monitoring for lack of benefit is particularly important. We review the complex nature of stopping a randomized trial for lack of benefit and argue that many cancer trials could be improved by a more aggressive approach to monitoring. On the other hand, we caution that some commonly used monitoring guidelines may result in stopping for lack of benefit even when a nontrivial beneficial effect is observed.Keywords
This publication has 44 references indexed in Scilit:
- Ethical, Scientific, and Regulatory Perspectives Regarding the Use of Placebos in Cancer Clinical TrialsJournal of Clinical Oncology, 2008
- Randomized Clinical Trial Design for Assessing Noninferiority When Superiority Is ExpectedJournal of Clinical Oncology, 2007
- Futility approaches to interim monitoring by data monitoring committeesClinical Trials, 2006
- Clinical trials in ovarian carcinoma: study methodologyAnnals Of Oncology, 2005
- Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trialThe Lancet, 2003
- The agonising negative trend in monitoring of clinical trialsThe Lancet, 1999
- The Design and Analysis of Sequential Clinical Trials.Published by JSTOR ,1997
- Five Years of Tamoxifen--or More?JNCI Journal of the National Cancer Institute, 1996
- Stopping when the experimental regimen does not appear to helpStatistics in Medicine, 1994
- Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapyThe Lancet, 1992